Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on July 19, 2021. The filing serves as a Regulation FD disclosure regarding a Research & Development Call focused on the Company's systemic complement regulator programs.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of non-financial corporate events and does not contain financial statements.
Material Changes
There are no material financial changes reported in this document. The primary event is the dissemination of information regarding the Company's complement programs and its first subcutaneously-dosed systemic complement development candidate.
Guidance, Outlook, and Management Commentary
- Event: On July 19, 2021, the Company presented on its complement programs and a new development candidate.
- Materials: The Company posted an updated Corporate Presentation and a specific Complement Presentation on its investor relations website.
- Legal Status: The information provided in this Item 7.01 and the attached exhibits is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Catalyst Biosciences, Inc. (Ticker: CBIO), as the input metadata incorrectly referenced Gyre Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Complement Presentation) and Exhibit 99.2 (Corporate Presentation) for specific clinical data and development timelines not detailed in the 8-K text.
- Confirm that the information in the presentations is not legally incorporated by reference into other SEC filings unless explicitly noted.